Alzecure: Reports positive phase II data in neuropathic pain with ACD440 - Redeye
Redeye endorses yesterday’s news that Alzecure has presented positive phase IIa data with ACD440 in neuropathic pain. We give our initial take and raise our base case.
ANNONS
Redeye endorses yesterday’s news that Alzecure has presented positive phase IIa data with ACD440 in neuropathic pain. We give our initial take and raise our base case.
